Global Pharmacogenomics Partnering Terms and Agreements 2010-2018: Deals and Agreements Entered into by the World's Leading Healthcare Companies.

Dublin, March 09, 2018 -- The "Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2018" report has been added to ResearchAndMarkets.com's offering.

The Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2018 report provides comprehensive understanding and unprecedented access to the pharmacogenomic partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Pharmacogenomics agreements announced in the healthcare sectors.

Pharmacogenomics focusses on the influence of genetic variation on drug response in patients by correlating gene expression or single nucleotide polymorphisms with a drug's efficacy or toxicity.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 300 links to online copies of actual pharmacogenomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Key benefits

Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2018 provides the reader with the following key benefits:

• In-depth understanding of pharmacogenomics deal trends since 2010
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of pharmacogenomics agreements with real life case studies
• Detailed access to actual pharmacogenomic contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a pharmacogenomic agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2018 includes:

• Trends in pharmacogenomics dealmaking in the biopharma industry since 2010
• Analysis of pharmacogenomic deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life pharmacogenomics deals
• Access to over 300 pharmacogenomics online deal records
• The leading pharmacogenomics deals by value since 2010
• Most active pharmacogenomics dealmakers since 2010
• The leading pharmacogenomics partnering resources

In Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2018, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
  

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Pharmacogenomics dealmaking

2.1. Introduction
2.2. Pharmacogenomics partnering over the years
2.3. Most active Pharmacogenomics dealmakers
2.4. Pharmacogenomics partnering by deal type
2.5. Pharmacogenomics partnering by therapy area
2.6. Deal terms for Pharmacogenomics partnering
2.6.1 Pharmacogenomics partnering headline values
2.6.2 Pharmacogenomics deal upfront payments
2.6.3 Pharmacogenomics deal milestone payments
2.6.4 Pharmacogenomics royalty rates

Chapter 3 - Leading Pharmacogenomics deals

3.1. Introduction
3.2. Top Pharmacogenomics deals by value

Chapter 4 - Most active Pharmacogenomics dealmakers

4.1. Introduction
4.2. Most active Pharmacogenomics dealmakers
4.3. Most active Pharmacogenomics partnering company profiles

Chapter 5 - Pharmacogenomics contracts dealmaking directory

5.1. Introduction
5.2. Pharmacogenomics contracts dealmaking directory

Chapter 6 - Pharmacogenomics dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

For more information about this report visit https://www.researchandmarkets.com/research/8hmrzs/global?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Genomics